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Tumour angiogenesis and the levels of plasminogen activator inhibitor type 1 (PAI-1) are both informative prognostic markers in
breast cancer. In cell cultures and in animal model systems, PAI-1 has a proangiogenic effect. To evaluate the interrelationship of
angiogenesis and the PAI-1 level in breast cancer, we have evaluated the prognostic value of those factors in a total of 228 patients
with primary, unilateral, invasive breast cancer, evaluated at a median follow-up time of 12 years. Microvessels were
immunohistochemically stained by antibodies against CD34 and quantitated by the Chalkley counting technique. The levels of
PAI-1 and its target proteinase uPA in tumour extracts were analysed by ELISA. The Chalkley count was not correlated with the
levels of uPA or PAI-1. High values of uPA, PAI-1, and Chalkley count were all significantly correlated with a shorter recurrence-free
survival and overall survival. In the multivariate analysis, the uPA level did not show independent prognostic impact for any of the
analysed end points. In contrast, the risk of recurrence was independently and significantly predicted by both the PAI-1 level and the
Chalkley count, with a hazard ratio (95% CI) of 1.6 (1.01–2.69) and 1.4 (1.02–1.81), respectively. For overall survival, the Chalkley
count, but not PAI-1, was of significant independent prognostic value. The risk of death was 1.7 (1.30–2.15) for Chalkley counts in the
upper tertile compared to the lower one. We conclude that the PAI-1 level and the Chalkley count are independent prognostic
markers for recurrence-free survival in patients with primary breast cancer, suggesting that the prognostic impact of PAI-1 is not only
based on its involvement in angiogenesis.
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Tumour growth can be dependent on angiogenesis, that is, the
formation of new blood vessels from the existing capillary
network (Folkman, 1971, 1995). Tumour progression seems to be
dependent on cancer cell controlled tissue remodelling, including
angiogenesis, mediated to a large extent by the plasminogen
activation system (Mignatti and Rifkin, 1996; Pepper et al, 1996;
Mazar et al, 1999). The hypothesis of angiogenesis as a
prognosticator has been widely investigated using different assays
for determining microvessel density (Fox, 1997; Hansen et al,
2000a). Angiogenesis determined by Chalkley counting has shown
independent prognostic value in a large population-based study of
primary breast cancer patients (Hansen et al, 2000b). Breast cancer
patients whose tumours had a Chalkley count in the upper tertile
had, compared to patients belonging to the lowest tertile, a 126%
increased risk of dying and patients in the middle tertile a 55%
increased risk (Hansen et al, 2000b). Likewise, the urokinase-type
(uPA) plasminogen activator system has been shown to play a
crucial role in cancer metastasis (Andreasen et al, 1997, 2000).
Various components of the uPA system, including uPA itself and
its primary inhibitor, plasminogen activator inhibitor type 1 (PAI-
1), have demonstrated significant prognostic impact in breast
cancer patients. Thus, the level of PAI-1 in primary tumours is one
of the most informative biochemical prognostic markers in several
cancer types (Duffy, 1996; Harbeck et al, 1998; Knoop et al, 1998;
Duffy et al, 1999; Look and Foekens, 1999; Janicke et al, 2001; Look
et al, 2002).
In several cell culture and animal model systems, PAI-1 has
been found to have a proangiogenic effect (Bajou et al, 1998,
2001; Lambert et al, 2001; McMahon et al, 2001; Devy et al,
2002). However, the clinical significance of the biological
interaction of angiogenesis and the plasminogen activator system
is unknown. Although the prognostic impacts of the Chalkley
count and PAI-1 have been reported individually in large
study populations, it is highly relevant to evaluate the combined
prognostic impact of angiogenesis and the levels of the compo-
nents of the plasminogen activator system in the same study
population.
The aims of the present study were to evaluate the association
between the Chalkley count, the levels of PAI-1 and of uPA, and
the independent prognostic value of these components in relation
to the classical prognostic factors in breast cancer.
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Patients
The study included 228 patients who underwent surgery for
primary, unilateral, invasive breast carcinoma. Inclusion was
restricted to patients referred from the primary catchment area of
Odense University Hospital during the period from 1 August 1984
to 1 September 1989. Mammographic screening for breast cancer
was not performed in the background population during this
period. Excluded were patients with distant metastasis at the time
of diagnosis, locally advanced disease, inflammatory carcinoma,
synchronous bilateral breast cancer, and a diagnosis of isolated
carcinoma in situ. Women with previous malignant disease, apart
from carcinoma in situ of the uterine cervix or nonmelanotic skin
cancer, were excluded, as were women who did not undergo
axillary dissection with at least one lymph node removed. The
analysis was restricted to those 228 patients who had residual
tumour material stored at  801C at the time of surgery. Earlier
we reported the Chalkley counts on a population-based cohort
of 836 patients (Hansen et al, 2000b). The 228 patients are a
subgroup of this cohort, sampled from a shorter period of time
(432 patients), and further restricted to patients having frozen
tumour material available. Also, we have earlier reported on uPA
and PAI-1 from a larger cohort of 429 patients based on frozen
tumour samples (Knoop et al, 1998). Again, the 228 patients are a
subgroup of this cohort restricted to the primary catchment area of
Odense University Hospital.
Treatment
Surgery, radiotherapy, and adjuvant systemic therapy were carried
out according to the nationwide recommendation of the Danish
Breast Cancer Cooperative Group (DBCG) (Andersen and Mour-
idsen, 1988). In all, 27 patients were treated with breast-conserving
surgery and all had postoperative irradiation. In total, 201 patients
underwent simple mastectomy, and of these 63 had postoperative
irradiation. High-risk patients (N1, T3 or T4) were offered
systemic adjuvant therapy according to the DBCG programme
(Fischerman and Mouridsen, 1988). In summary, 42 patients had
primary chemotherapy (CMF), 50 patients primary endocrine
therapy (tamoxifen), and 12 both endocrine therapy and chemo-
therapy. A total of 124 patients received no systemic treatment:
of these 82 were considered low-risk (N0, T1–2) patients, while 42
patients were either too old or were found to have some medical
contraindications for systemic treatment.
Follow-up
Patients were followed up on a regular basis for the first 10 years at
Odense University Hospital according to the DBCG recommenda-
tions (Andersen and Mouridsen, 1988). After the first 10 years,
information about recurrence was obtained by studying the
clinical records from the treating department. Patients were
followed until the time of the last contact or death, or until the
closing date of the study, 1 March 1999. The median follow-up
time was 12 years and 1/2 month.
End points
The prognostic analysis was primarily carried out using recur-
rence-free survival (RFS) and overall survival (OS). The RFS
analysis was based on time to first recurrence at any site including
89 events. Thus, patients who died without recurrence were
censored. The OS analysis was based on death from any cause
comprising 118 events.
Histopathology
The histological type of breast tumour was determined according
to the WHO guidelines (Scharff and Torloni, 1998). Histological
malignancy grading followed the grading system of Bloom and
Richardson (1957). Tumour size was measured as the largest
diameter of the invasive carcinoma. Receptor status was retrieved
from the DBCG database and considered positive if the estrogen
receptor (ER) or progesterone receptor (PgR) value by the
dextran-coated charcoal (DCC) method was greater than or equal
to 10fmolmg
 1 cytosol protein. Where the DCC method was
unavailable, a positive receptor status was determined by an
immunohistochemical ER staining (antibody clone 1D5, DAKO,
Glostrup, Denmark). ER-positive was defined as X10% of the
tumour cells staining positively.
Angiogenesis
The estimation of angiogenesis by Chalkley counts has been
described in detail earlier (Hansen et al, 2000b). Briefly, one 4mm
thick section from each formalin-fixed and paraffin-embedded
tumour was mounted on a ChemMate slide (DAKO, Glostrup,
Denmark). Epitope retrieval was performed by microwave heating
in a buffer of 10mm Tris (pH 9), 0.5mm EGTA. As primary
antibody against CD34, we used clone QBEnd/10 (Novo Castra,
Newcastle, UK), diluted 1:20, with overnight incubation at 41C.
The angiogenesis assessed by the Chalkley count technique was
based on scanning the tumour section at low magnification and
choosing three of the most vascularised areas (hot-spots), which
were assumed to have the highest number of microvessel profiles.
Using a higher magnification, a 25-point Chalkley graticule was
applied to each hot-spot and oriented to permit the maximum
number of points to hit the immunohistochemically highlighted
microvessel profiles (Leitz Ortoplane;  250; Chalkley grid area
0.196mm
2). The Chalkley count was taken as the mean value of the
three counts for each tumour. The Chalkley count is given as the
number of hitting points without a unit; measurement range 0–25.
uPA and PAI-1
The antigen levels of uPA and PAI-1 were assessed with ELISA as
described in detail earlier (Knoop et al, 1998). Briefly, tissue for
analysis was taken from  801C, homogenised in a buffer of 0.1mm
Tris (pH 8.1), 0.5% Triton X-100, 10mm EDTA, 10mgml
 1
aprotinin (10ml buffer per mg tissue), and centrifuged. The
supernatants were analysed. For the uPA ELISA, monoclonal anti-
uPA IgG from hybridoma clones 2, 6, and 12 was used on the solid
phase. For the PAI-1 ELISA, monoclonal anti-PAI-1 IgG from
hybridoma clone 2 was used on the solid phase. The second
antibody layer consisted of polyclonal rabbit anti-uPA or rabbit
anti-PAI-1 antibodies. As the third layer, we used peroxidase-
conjugated swine antibodies against rabbit antibodies for both
ELISAs. The levels of uPA or PAI-1 were expressed as ng per mg
total protein in the extracts.
Statistics
Angiogenesis, PAI-1, and uPA were estimated without knowledge
of the clinical data or prognostic outcome. Predetermined cutoff
points from the earlier studies (Knoop et al, 1998; Hansen et al,
2000b) were used for the prognostic analysis: Chalkley count at
5 and 7 points, PAI-1 at 11.1ngmg
 1 total protein, and uPA
at 4.5ngmg
 1 total protein. The relationship between the Chalkley
count, the PAI-1 level, and the uPA level were tested by the
Spearman correlation test. The possible associations of the
classical clinical pathological parameters on one side and
the Chalkley count, the PAI-1 level, and the uPA level on the other
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relationship between prognostic variables and the follow-up end
points was illustrated by Kaplan–Meier plots of survival
probabilities (Kaplan and Meier, 1958), and the survival functions
were compared by the log-rank test. The multivariate relationship
was evaluated by the Cox proportional hazard regression analysis
(Cox, 1972). To obtain acceptable statistical strength in the
multivariate analysis, it has been suggested that the number of
events should be at least 10 times the total number of variables
included (Harrell et al, 1985; Simon and Altman, 1994; Peduzzi
et al, 1996). In this study, with a limited number of events, it is
not advisable to introduce many covariates, and this was the
reason for not estimating the prognostic effect of each subgroup
of the variable. Therefore, the risk estimates for each variables
are an average between subgroups; that is, lowest to middle to
highest tertile. Thus, using eight variables in our Cox models, we
assumed that we could achieve a reliable statistical strength of
the risk estimates in the multivariate regression analysis. As in
the earlier publication (Knoop et al, 1998), the Cox models
included the classical prognostic factors (menopausal status,
tumour size, malignancy grade, receptor status, and number of
positive nodes) together with uPA, PAI-1, and the Chalkley count,
in that order. The Cox models were stratified by receptor status,
which did not fulfil the assumption of proportional hazard rates.
Two-sided P-values below 0.05 were considered to be statistically
significant.
RESULTS
Clinical data
The tertiles of the Chalkley estimates were 5.3 and 7.0 points, of the
PAI-1 levels 8.1 and 15.1ngmg
 1 total protein, and of the uPA
levels 3.2 and 6.3ngmg
 1 total protein. The median (range) of
the Chalkley count was 6.0 (2.7–13.0), of PAI-1 11.1ngmg
 1
(0.1–73.0), and of uPA of 4.7ngmg
 1 (0.3–21.6). Table 1 shows
the distributions of the clinical and pathological data of the
patients in the study population and the distribution of the
Chalkley count, the PAI-1 level, and the uPA level. A high Chalkley
count was significantly associated with large tumour size, high
histological malignancy grade, negative receptor status, but not
with a high number of axillary lymph node metastases, age, or
menopausal status. A high PAI-1 level was significantly associated
with large tumour size, high histological malignancy grade, negative
receptor status, and a high number of axillary lymph node metastases,
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Table 1 Description of clinicopathological data and the association with the Chalkley count, PAI-1 levels and uPA
levels
Chalkley count PAI-1 uPA
(points) (ngmg
 1 total protein) (ng mg
 1 total protein)
Variables N (%) Median Median Median
All 228 (100) 6.0 11.05 4.65
Age (years)
o40 11 (5) 6.3 11.4 4.2
40–49 41 (18) 6.1 10.7 3.3
50–59 51 (22) 6.0 10.1 5.0
60–69 60 (26) 6.3 11.3 4.9
X70 65 (29) 5.7 11.3 5.5
P=0.99 P=0.90 P=0.69
Menopausal status
Pre 68 (30) 6.2 10.6 4.2
Post 160 (70) 6.0 11.3 5.0
P=0.86 P=0.31 P=0.27
Tumour size (mm)
p20 86 (38) 5.7 10.5 3.8
21–50 132 (58) 6.3 12.7 5.7
>50 10 (4) 6.5 8.1 3.0
P=0.004 P=0.019 P=0.004
Histological malignancy grade
I (ductal) 36 (16) 5.2 9.6 4.4
II (ductal) 87 (38) 6.0 12.1 5.4
III (ductal) 74 (32) 7.0 12.9 5.5
Other (nonductal) 31 (14) 5.1 5.1 1.8
Po0.001 Po0.001 Po0.001
Receptor status
Positive 174 (76) 5.7 10.8 4.5
Negative 54 (24) 7.7 12.9 5.6
Po0.001 P=0.027 P=0.069
Lymph node metastasis
None 101 (44) 6.0 9.7 4.2
1–3 78 (34) 6.0 12.5 5.4
X4 49 (22) 6.7 14.7 5.2
P=0.82 P=0.008 P=0.055
Significant associations are given in bold.
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British Journal of Cancer (2003) 88(1), 102–108 & 2003 Cancer Research UKbut not with age or menopausal status. A high uPA level was
significantly associated with large tumour size, high histological
malignancy grade, and marginally significantly associated with
negative receptor status and a high number of positive axillary
lymph node metastases, but not with age or menopausal status.
Association
Figure 1 shows scatter plots illustrating the relationship between
the Chalkley count, the PAI-1 level, and the uPA level. High levels
of uPA were weakly linearly associated with high levels of PAI-1
(r¼0.57, Po0.001). In contrast to this, there was no indication of
an association between the Chalkley count and PAI-1 or uPA levels
in primary breast carcinomas.
Univariate analysis
The Kaplan–Meier plots in Figure 2 illustrate the significantly
poorer prognostic outcome for patients with high Chalkley counts
(P¼0.0029, RFS; Po0.0001, OS), high PAI-1 levels (P¼0.0001,
RFS; P¼0.0004, OS), and high uPA levels (P¼0.0328, RFS;
P¼0.0354, OS). The 5-year-survival probabilities for the three
investigated factors as well as the classical prognostic factors in
breast cancer are tabulated in Table 2. Among the classical
prognostic factors, the univariate analysis showed a significantly
poorer prognostic outcome for patients with large tumour size
(P¼0.0004, RFS; P¼0.0002, OS), high histological malignancy
grade (P¼0.0061, RFS; P¼0.0007, OS), high number of positive
axillary lymph nodes (Po0.0001 for both RFS and OS), while
postmenopausal patients had a significantly poorer outcome only
for OS (P¼0.011).
Multivariate analysis
Table 3 shows the results of the Cox multivariate regression
analysis including the classical prognostic factors (menopausal
status, tumour size, histological malignancy grade, receptor status,
and number of axillary lymph node metastases) as well as the
levels of uPA and PAI-1 and the Chalkley count, which were
introduced in the model in that order. The cutoff values from
Table 1 were used for the classical factors, while the cutoff values
for the levels of uPA and PAI-1 and the Chalkley count were used
as defined in earlier studies (Knoop et al, 1998; Hansen et al,
2000b). The nonductal carcinomas were grouped with ductal
malignancy grade II carcinomas because they had approximately
the same survival. Using the recurrence-free survival as an
endpoint, there was significant independent information from
tumour size, lymph node metastasis, PAI-1, and Chalkley count.
There was a 70% increased risk of recurrence (HR¼1.7 (1.02–
2.72)) for patients with PAI-1 values above the median as
compared to values below the median. There was a 40% increased
risk of recurrence (HR¼1.4 (1.03–1.84)) for patients with
Chalkley counts in the middle tertiles as compared to the lowest
tertile, and a further 40% increase in the risk of recurrence in
having a Chalkley count in the upper tertile as compared to the
middle tertile. Analysing overall survival, menopausal status,
tumour size, malignancy grade, lymph node metastasis, and
Chalkley counts showed a significant independent prognostic
value. There was a 70% increase in the risk of dying (HR¼1.7
(1.32–2.20)) for patients with Chalkley counts going from one
tertile to the next.
DISCUSSION
Angiogenesis and extracellular proteolysis of the plasminogen
activation system are of crucial importance in cancer metastasis
(Andreasen et al, 1997). A clinical usefulness of these systems to
predict the outcome in breast cancer patients has been expected.
Numerous studies have established a prognostic value of the levels
of uPA and PAI-1 and of angiogenesis in breast cancer patients
(Fox, 1997; Harbeck et al, 1998; Duffy et al, 1999; Look and
Foekens, 1999; Look et al, 2002). However, none of these factors
are yet used in current clinical practice.
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Figure 1 Relationships between the levels of uPA, PAI-1, and the
Chalkley count.
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British Journal of Cancer (2003) 88(1), 102–108 & 2003 Cancer Research UKThe biological interpretation of the prognostic impact of high
values of uPA and of angiogenesis has been straightforward. A
high number of vessel profiles should increase the nourishment
and growth of the tumour and allow access of tumour cells to the
circulation. High uPA levels facilitate the proteolytic degradation
of the basement membranes and extracellular matrix, and thereby
increase the invasive ability and metastatic potential. Moreover,
angiogenesis is believed to require extracellular proteolytic
activity, including uPA activity (Mignatti and Rifkin, 1996; Pepper
et al, 1996; Mazar et al, 1999). The prognostic impact of high levels
of PAI-1 has been more difficult to explain. Generally, we could
expect a requirement for the presence of proteinase inhibitors
during tissue remodelling events, because of a need to restrict
proteolysis in time and space. Hence, the association of high PAI-1
levels with a poor prognostic outcome can be explained by a
requirement for local downregulation of the proteolytic activity. In
particular, proteolytic downregulation could support a local
protection of the basement membrane surrounding the sprouting
endothelial cells. This could further facilitate the capillary
networking of the new tumour blood vessels. Accordingly, it has
been reported that tumour angiogenesis is drastically impaired in
mice with targeted disruption of the PAI-1 gene (Bajou et al, 1998,
2001). A few other model system studies have also suggested a
proangiogenic role of PAI-1 (Lambert et al, 2001; McMahon et al,
2001; Devy et al, 2002). In particular, the possible role of uPA and
PAI-1 in angiogenesis was of interest in the preparation of the
present study. Owing to the above explanations, we had reasons to
expect biological relations between levels of the components of the
plasminogen activating system, especially PAI-1, and the angio-
genic process. One might expect PAI-1 to be a surrogate marker
for the angiogenic activity. This could be expected to be seen as a
positive association between PAI-1 and the Chalkley count, and
possibly a prognostic value of PAI-1 and the Chalkley count being
dependent on each other.
In general, the estimates of the Chalkley count, PAI-1, and uPA
from this study are in agreement with our earlier reports (Knoop
et al, 1998; Hansen et al, 2000b). In the present study, the Chalkley
count was not associated with the levels of uPA or PAI-1. This is
in accordance with another report (Fox et al, 2001) showing
no association between the Chalkley count and uPA or PAI-1.
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Figure 2 Kaplan–Meier plots of the survival probabilities for the different categories of the Chalkley count, the uPA level, and the PAI-1 level. The survival
curves in the upper row give the probabilities of overall survival, and in the bottom row the probabilities of recurrence-free survival. Predefined cutoff values
(see Statistics section) were 4.5ngmg
 1 total protein for the uPA level, 11.1ngmg
 1 total protein for the PAI-1 level, and 5 and 7 points for the Chalkley
count. The number of patients at risk in each group is given at 0-, 5-, and 10-years follow-up.
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British Journal of Cancer (2003) 88(1), 102–108 & 2003 Cancer Research UKHowever, that study did not evaluate the independent prognostic
value of the Chalkley count in relation to the uPA or PAI-1 levels,
because of an ‘insufficient number of events for the number of
variables’ (Fox et al, 2001). Others have reported a moderate
association between angiogenesis and uPA (r¼0.85), as well as
PAI-1 (r¼0.74) (Hildenbrand et al, 1995). This might be explained
from the fewer (n¼42) patients investigated in those studies, from
correlating uPA from the periphery of the tumour specimen with
the angiogenesis, and from estimating angiogenesis by the
microvessel density method. We chose the Chalkley count estimate
of angiogenesis, since this assay is somewhat less influenced by the
observer variation (Hansen et al, 1998), and because it has a
stronger prognostic value as compared to the microvessel density
assay (Rose et al, 2000). The frozen tumour specimens used for the
uPA and PAI-1 analyses do not represent the same tumour areas as
the paraffin-embedded specimens used for the Chalkley counts.
Owing to the tumour heterogeneity, the tumour values of
biologically related factors obtained from estimates in different
regions may not be associated, although measurements of the
factors obtained from the same areas would be associated. The
levels of PAI-1 and uPA were low in very large tumours (450mm)
and in nonductal carcinomas. Hence, it is necessary to be aware of
possible sampling errors, which in large tumours could be affected
by necrotic areas, and in lobular carcinomas by the lower
cellularity compared to the ductal carcinomas.
The independent prognostic effect of the Chalkley count was
approximately of the same magnitude as reported earlier (Fox et al,
1995; Hansen et al, 2000b). In accordance with our earlier findings
(Knoop et al, 1998), the uPA did not reveal any independent
prognostic value. The PAI-1 estimate did have independent
prognostic impact regarding the risk of recurrence as in our earlier
report (Knoop et al, 1998). The PAI-1 estimate did not provide a
significant independent prognostic value for the risk of death in the
present smaller sample of the former population. This was also the
case in a Cox model not including the Chalkley count (data not
shown). We stratified the Cox multivariate models by receptor
status, because it does not fulfil the assumption of proportional
hazards. Hence, the independent prognostic estimates of uPA, PAI-
1 and the Chalkley count are adjusted for the effect of the receptor
status as well as the other classical prognostic factors included.
The lack of correlation between the level of PAI-1 and the
Chalkley count at first sight appears in contradiction to the
hypothesis of PAI-1 being implicated in angiogenesis, as discussed
above. Several explanations may be offered for the lack of
correlation. First, the angiogenesis may be regulated differently
in the human breast tumours studied here and in the experimental
models discussed above. Second, if PAI-1 is implicated in the
angiogenic process, it may only be transiently expressed and its
level may therefore be associated with the rate of vessel formation
rather than the accumulated amount of vessels, represented by the
Chalkley count (Fox et al, 2001). Third, it is because of
heterogeneity of the level of PAI-1 and the Chalkley count within
the tumour, as discussed above. Fourth, PAI-1 may have a
multitude of functions in breast tumours, angiogenesis only being
one among several. The latter hypothesis is favoured by the
immunohistochemical localization of PAI-1 to several cell types in
breast tumours, including not only endothelial cells but also
fibroblasts and cancer cells (Christensen et al, 1996).
The major finding in our present investigation is the
independent prognostic impact of both the PAI-1 and the Chalkley
count in the same primary breast tumours. This fits well with the
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Table 2 Five-year survival probabilities7s.e. in percentages for recur-
rence-free survival (RFS), and overall survival (OS)
RFS OS
Variables N %( 7s.e.) % (7s.e.)
All 228 68 (3) 67 (3)
Menopausal status
Pre 68 67 (6) 74 (5)
Post 160 68 (4) 64 (4)
P=0.926 P=0.011
Tumour size (mm)
p20 86 83 (4) 81 (4)
21–50 132 59 (4) 59 (4)
>50 10 40 (15) 40 (15)
P=0.0004 P=0.0002
Histological malignancy grade
I (ductal) 36 88 (5) 92 (5)
II (ductal) 87 66 (5) 69 (5)
III (ductal) 74 55 (6) 49 (6)
Other (nonductal) 31 76 (8) 74 (8)
P=0.0061 P=0.0007
Receptor status
Positive 174 69 (4) 68 (4)
Negative 54 64 (7) 63 (7)
P=0.881 P=0.857
Lymph node metastasis
None 101 75 (4) 77 (4)
1–3 78 78 (5) 72 (5)
X4 49 37 (7) 37 (7)
Po0.0001 Po0.0001
Chalkley count (points)
p5 75 84 (4) 84 (4)
5–7 72 61 (6) 68 (5)
X7 81 58 (6) 49 (6)
P=0.0029 Po0.0001
PAI-1 (ngmg
 1 total protein)
p11.1 117 79 (4) 74 (4)
>11.1 111 56 (5) 59 (5)
P=0.0001 P=0.0004
uPA (ngmg
 1 total protein)
p4.5 113 75 (4) 73 (4)
>4.5 115 60 (5) 60 (5)
P=0.0328 P=0.0354
Significant differences in survival probabilities between the groups are given in bold.
Table 3 The Cox multivariate analysis estimated the hazard ratios (HR)
and 95% CI for the risk of recurrence (RFS) and risk to die (OS) in a group
of 228 patients with breast cancer
RFS OS
Variables P HR (95% CI) P HR (95% CI)
Menopausal status 0.91 1.0 (0.61–1.55) 0.003 2.0 (1.26–3.12)
Tumour size 0.015 1.7 (1.10–2.57) 0.014 1.6 (1.10–2.23)
Malignancy grade 0.081 1.4 (0.96–1.93) 0.011 1.5 (1.10–2.09)
Lymph node status o0.0001 1.9 (1.40–2.50) o0.0001 2.0 (1.53–2.52)
UPA 0.33 1.3 (0.79–2.01) 0.60 1.1 (0.74–1.67)
PAI-1 0.040 1.7 (1.02–2.72) 0.28 1.3 (0.83–1.92)
Chalkley count 0.032 1.4 (1.03–1.84) o0.0001 1.7 (1.32–2.20)
The variables were grouped as given in Table 2. The nonductal carcinomas were
included in the group of grade II ductal carcinomas. The Cox models were stratified
by oestrogen receptor status, which did not fulfill the assumption of proportional
hazard rates. Bold P-values are given for variables with hazard ratios significantly
different from one.
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dently contribute to the regulation of tumour progression. In
conclusion, both PAI-1 and the Chalkley count added significant
and independent prognostic information on RFS in patients with
primary breast cancer.
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